Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Payables (2016 - 2025)

Anaptysbio (ANAB) has disclosed Payables for 10 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 3.27% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Dec 2025, down 3.27%, and an annual FY2025 reading of $3.9 million, down 3.27% over the prior year.
  • Payables was $3.9 million for Q4 2025 at Anaptysbio, up from $2.9 million in the prior quarter.
  • Across five years, Payables topped out at $6.5 million in Q3 2023 and bottomed at $1.6 million in Q2 2022.
  • Average Payables over 5 years is $3.8 million, with a median of $3.7 million recorded in 2024.
  • The sharpest move saw Payables crashed 71.39% in 2021, then soared 200.0% in 2023.
  • Year by year, Payables stood at $1.7 million in 2021, then surged by 59.91% to $2.8 million in 2022, then soared by 68.75% to $4.7 million in 2023, then fell by 14.81% to $4.0 million in 2024, then fell by 3.27% to $3.9 million in 2025.
  • Business Quant data shows Payables for ANAB at $3.9 million in Q4 2025, $2.9 million in Q3 2025, and $3.3 million in Q2 2025.